Half-year report · Q2
3353.TEDINET S100WUVY
Period2025-03-01 → 2025-08-31
Filed2025-10-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥26.9bn | 2025-03-01 → 2025-08-31 | Cons. | Net sales |
| Revenue | ¥48.4bn | 2024-03-01 → 2025-02-28 | Cons. | Net sales (5-year summary) |
| Revenue | ¥22.7bn | 2024-03-01 → 2024-08-31 | Cons. | Net sales |
| Operating income | ¥744m | 2025-03-01 → 2025-08-31 | Cons. | Operating income |
| Operating income | ¥828m | 2024-03-01 → 2024-08-31 | Cons. | Operating income |
| Ordinary income | ¥880m | 2025-03-01 → 2025-08-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.8bn | 2024-03-01 → 2025-02-28 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥853m | 2024-03-01 → 2024-08-31 | Cons. | Ordinary income |
| Profit before tax | ¥1.0bn | 2025-03-01 → 2025-08-31 | Cons. | Income before income taxes |
| Profit before tax | ¥1.1bn | 2024-03-01 → 2024-08-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥667m | 2025-03-01 → 2025-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.1bn | 2024-03-01 → 2025-02-28 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥710m | 2024-03-01 → 2024-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥691m | 2025-03-01 → 2025-08-31 | Cons. | Profit loss |
| Net income | ¥728m | 2024-03-01 → 2024-08-31 | Cons. | Profit loss |
| Total assets | ¥37.9bn | at 2025-08-31 | Cons. | Assets |
| Total assets | ¥34.2bn | at 2025-02-28 | Cons. | Assets |
| Total assets | ¥33.1bn | at 2024-08-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥22.6bn | at 2025-08-31 | Cons. | Liabilities |
| Total liabilities | ¥19.5bn | at 2025-02-28 | Cons. | Liabilities |
| Net assets / equity | ¥15.3bn | at 2025-08-31 | Cons. | Net assets |
| Net assets / equity | ¥14.7bn | at 2025-02-28 | Cons. | Net assets |
| Net assets / equity | ¥14.4bn | at 2024-08-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥8.6bn | at 2025-08-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.8bn | at 2025-02-28 | Cons. | Cash and deposits |
| Cash & equivalents | ¥8.1bn | at 2025-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.6bn | at 2025-02-28 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥8.1bn | at 2024-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.6bn | at 2024-02-29v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.5bn | 2025-03-01 → 2025-08-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.2bn | 2024-03-01 → 2025-02-28 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.5bn | 2024-03-01 → 2024-08-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥987m | 2025-03-01 → 2025-08-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2024-03-01 → 2025-02-28 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥675m | 2024-03-01 → 2024-08-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.0bn | 2025-03-01 → 2025-08-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.0bn | 2024-03-01 → 2025-02-28 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥354m | 2024-03-01 → 2024-08-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥177.23 | 2025-03-01 → 2025-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥301.35 | 2024-03-01 → 2025-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥188.75 | 2024-03-01 → 2024-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 38.6% | at 2025-08-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.2% | at 2025-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.6% | at 2024-08-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-03-01 → 2025-08-31 | −¥561m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-03-01 → 2025-08-31 | −¥561m |
| Reconciling Itemsreconciling | segment profit | 2025-03-01 → 2025-08-31 | −¥94m |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2025-03-01 → 2025-08-31 | ¥13.1bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2025-03-01 → 2025-08-31 | ¥13.1bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2025-03-01 → 2025-08-31 | ¥658m |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue | 2025-03-01 → 2025-08-31 | ¥4.4bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue external | 2025-03-01 → 2025-08-31 | ¥4.4bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue intersegment | 2025-03-01 → 2025-08-31 | ¥300,000 |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | segment profit | 2025-03-01 → 2025-08-31 | ¥14m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue | 2025-03-01 → 2025-08-31 | ¥9.9bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2025-03-01 → 2025-08-31 | ¥9.4bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2025-03-01 → 2025-08-31 | ¥555m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2025-03-01 → 2025-08-31 | ¥90m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue | 2025-03-01 → 2025-08-31 | ¥126m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue external | 2025-03-01 → 2025-08-31 | ¥120m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue intersegment | 2025-03-01 → 2025-08-31 | ¥5m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | segment profit | 2025-03-01 → 2025-08-31 | ¥75m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-03-01 → 2025-08-31 | ¥27.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-03-01 → 2025-08-31 | ¥26.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-03-01 → 2025-08-31 | ¥561m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-03-01 → 2025-08-31 | ¥837m |
| Reconciling Itemsreconciling | revenue | 2024-03-01 → 2024-08-31 | −¥401m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-03-01 → 2024-08-31 | −¥401m |
| Reconciling Itemsreconciling | segment profit | 2024-03-01 → 2024-08-31 | −¥110m |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥551m |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥4.0bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥4.0bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥300,000 |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥128m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥7.1bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥6.7bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥399m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥194m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥93m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥91m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥2m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥65m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-03-01 → 2024-08-31 | ¥23.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-03-01 → 2024-08-31 | ¥22.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥401m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-03-01 → 2024-08-31 | ¥938m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 529
| Item | Context | Value | Unit |
|---|---|---|---|
| Other noi | CurrentYTDDuration | 44237000 | JPY |
| Non operating income | Prior1YTDDuration | 78772000 | JPY |
| Non operating income | CurrentYTDDuration | 207892000 | JPY |
| Interest expenses noe | Prior1YTDDuration | 26972000 | JPY |
| Interest expenses noe | CurrentYTDDuration | 46227000 | JPY |
| Loss on investing in marketable securities noe | Prior1YTDDuration | 7144000 | JPY |
| Loss on investing in marketable securities noe | CurrentYTDDuration | 3816000 | JPY |
| Other noe | Prior1YTDDuration | 19952000 | JPY |
| Other noe | CurrentYTDDuration | 20981000 | JPY |
| Non operating expenses | Prior1YTDDuration | 54069000 | JPY |
| Non operating expenses | CurrentYTDDuration | 71025000 | JPY |
| Ordinary income | Prior1YTDDuration | 853019000 | JPY |
| Ordinary income | CurrentYTDDuration | 880488000 | JPY |
| Gain on sales of noncurrent assets ei | Prior1YTDDuration | 76811000 | JPY |
| Gain on sales of noncurrent assets ei | CurrentYTDDuration | 4682000 | JPY |
| Gain on sales of investment securities ei | Prior1YTDDuration | 102748000 | JPY |
| Gain on sales of investment securities ei | CurrentYTDDuration | 199869000 | JPY |
| Gain on negative goodwill ei | Prior1YTDDuration | － | JPY |
| Gain on negative goodwill ei | CurrentYTDDuration | 41591000 | JPY |
| Subsidy ei | Prior1YTDDuration | － | JPY |
| Subsidy ei | CurrentYTDDuration | 35000000 | JPY |
| Settlement received ei | Prior1YTDDuration | 110000000 | JPY |
| Settlement received ei | CurrentYTDDuration | － | JPY |
| Extraordinary income | Prior1YTDDuration | 289560000 | JPY |
| Extraordinary income | CurrentYTDDuration | 281143000 | JPY |
| Loss on retirement of noncurrent assets el | Prior1YTDDuration | 1406000 | JPY |
| Loss on retirement of noncurrent assets el | CurrentYTDDuration | 783000 | JPY |
| Loss on reduction of noncurrent assets el | Prior1YTDDuration | － | JPY |
| Loss on reduction of noncurrent assets el | CurrentYTDDuration | 35000000 | JPY |
| Loss on sales of investment securities el | Prior1YTDDuration | 808000 | JPY |
| Loss on sales of investment securities el | CurrentYTDDuration | 147000 | JPY |
| Directors retirement benefits el | Prior1YTDDuration | － | JPY |
| Directors retirement benefits el | CurrentYTDDuration | 2050000 | JPY |
| Loss on cancellation of leasehold contracts el | Prior1YTDDuration | 3766000 | JPY |
| Loss on cancellation of leasehold contracts el | CurrentYTDDuration | 87288000 | JPY |
| Extraordinary loss | Prior1YTDDuration | 5982000 | JPY |
| Extraordinary loss | CurrentYTDDuration | 125270000 | JPY |
| Income before income taxes | Prior1YTDDuration | 1136597000 | JPY |
| Income before income taxes | CurrentYTDDuration | 1036361000 | JPY |
| Income taxes current | Prior1YTDDuration | 410883000 | JPY |
| Income taxes current | CurrentYTDDuration | 382849000 | JPY |
| Income taxes deferred | Prior1YTDDuration | -2198000 | JPY |
| Income taxes deferred | CurrentYTDDuration | -37729000 | JPY |
| Income taxes | Prior1YTDDuration | 408684000 | JPY |
| Income taxes | CurrentYTDDuration | 345120000 | JPY |
| Profit loss | Prior1YTDDuration | 727912000 | JPY |
| Profit loss | CurrentYTDDuration | 691241000 | JPY |
| Profit loss attributable to non controlling interests | Prior1YTDDuration | 18408000 | JPY |
| Profit loss attributable to non controlling interests | CurrentYTDDuration | 24385000 | JPY |
| Profit loss attributable to owners of parent | Prior1YTDDuration | 709504000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |